CAMP4 Therapeutics Corporation(CAMP)

Biotechnology · Cambridge, MA

$3.88-0.13 (-3.15%)

Delayed quote: Oct 6, 2026, 11:05 AM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T15:06:01.701Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:06:01.701Z.

Quote observation: 2026-10-06T15:05:17.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 243,708,328
TTM operating cash flow · period ending 2026-06-30: -28,591,000

FMP input reference: 5c882cca81b2c0fe2c09916b57b0a50c93804d18514abf2397940823ad07c5bd

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CAMP Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

CAMP Competitors' Price/OCF Ratio

CAMP

CAMP4 Therapeutics Corporation

Current

Market Cap

$243.71M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LFCR

Lifecore Biomedical, Inc.

vs CAMP

Market Cap

$243.82M

Price/OCF Ratio

N/A

TTM Avg

252.82

3Y Avg

252.82

5Y Avg

155.13

GALT

Galectin Therapeutics Inc.

vs CAMP

Market Cap

$241.69M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IFRX

InflaRx N.V.

vs CAMP

Market Cap

$241.56M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKBA

Akebia Therapeutics, Inc.

vs CAMP

Market Cap

$240.60M

Price/OCF Ratio

5.79

TTM Avg

7.79

3Y Avg

7.79

5Y Avg

7.79

IVVD

Invivyd, Inc.

vs CAMP

Market Cap

$247.23M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLSI

Greenwich LifeSciences, Inc.

vs CAMP

Market Cap

$245.86M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAUT

Nautilus Biotechnolgy, Inc.

vs CAMP

Market Cap

$243.85M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HITI

High Tide Inc.

vs CAMP

Market Cap

$237.69M

Price/OCF Ratio

13.29

TTM Avg

11.46

3Y Avg

10.55

5Y Avg

21.56

BIOA

BioAge Labs Inc.

vs CAMP

Market Cap

$236.82M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
CAMP4 Therapeutics Corporation (CAMP)	$243.71M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$243.82M	N/A	252.82	252.82	155.13
Galectin Therapeutics Inc. (GALT)vs ›	$241.69M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$241.56M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$240.60M	5.79	7.79	7.79	7.79
Invivyd, Inc. (IVVD)vs ›	$247.23M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$245.86M	N/A	N/A	N/A	N/A
Nautilus Biotechnolgy, Inc. (NAUT)vs ›	$243.85M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$237.69M	13.29	11.46	10.55	21.56
BioAge Labs Inc. (BIOA)vs ›	$236.82M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

CAMP Price/OCF Ratio Metrics

CAMP Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics